Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical TechnologyTelomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC. RegulatoryOncologyRead full story Post navigation Previous: ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower doseNext: Symeres and Ambagon collaborate for colorectal cancer molecules Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026